United States. Securities and Exchange Commission
GlycoMimetics, Inc. has filed a FORM 8-K with the U.S. Securities and Exchange Commission on January 2, 2024, announcing an entry into a project agreement with Patheon Manufacturing Services LLC. The agreement, which is subject to the terms of a Master Services Agreement, will have Patheon manufacture and supply
United States. Securities and Exchange Commission
Canoo Inc. held its annual meeting on December 29, 2023, where shareholders voted on several proposals. The meeting was attended by a quorum of shareholders, with 368,870,802 shares present, either online or by proxy. The election of directors, compensation of named executive officers, and ratification of the appointment
United States. Securities and Exchange Commission
Helix Energy Solutions Group, Inc. (HELIX) has completed the repurchase of its 6.75% Convertible Senior Notes due 2026 in a deal worth $160 million, with the company exchanging approximately 1.5 million shares of its common stock for the notes. The transaction was completed on December 27, 2023. In
United States. Securities and Exchange Commission
Coherus BioSciences, Inc. announced the U.S. Food and Drug Administration's approval of UDENYCA ONBODYtm, a pegfilgrastim biosimilar administered via an on-body injector (OBI) to reduce the incidence of infection as manifested by febrile neutropenia. The approval was supported by comprehensive analytical and clinical data, including pharmacokinetic and
United States. Securities and Exchange Commission
In a regulatory filing made on December 22, 2023, Xcel Energy Inc. announced that its subsidiary, Southwestern Public Service Company (SPS), has filed an electric rate case with the Public Utility Commission of Texas (PUCT) seeking a base rate increase of $149 million, which would translate to a 13% impact
United States. Securities and Exchange Commission
United Therapeutics Corporation, the manufacturer of Tyvaso and Tyvaso DPI, received a significant blow from the U.S. Court of Appeals for the Federal Circuit on December 20, 2023. The court's decision regards United Therapeutics' U.S. Patent No. 10,716,793, which was challenged by Liquidia
United States. Securities and Exchange Commission
Peggy Alford, Executive Vice President of Global Sales at PayPal Holdings, Inc., will cease to serve in her current role effective December 31, 2023, and will depart from the company on January 31, 2024. The departure is a planned transition and does not reflect any dispute or disagreement with the
United States. Securities and Exchange Commission
TMC the Metals Company Inc. has filed a current report on Form 8-K with the U.S. Securities and Exchange Commission (SEC), detailing updates on its ocean mining efforts and disruptions caused by Greenpeace International. The company has filed a "universal shelf" registration statement on Form S-3, allowing
United States. Securities and Exchange Commission
EchoStar Corporation has filed a Form 8-K with the U.S. Securities and Exchange Commission announcing the appointment of Hamid Akhavan, the current Chief Executive Officer and President of EchoStar, as the new President and Chief Executive Officer of DISH Network Corporation, effective November 13, 2023. This move follows the
United States. Securities and Exchange Commission
Neurocrine Biosciences, Inc., a Delaware-based biopharmaceutical company, has resolved patent litigation with Lupin Limited, a global pharmaceutical company, regarding its medication Ingrenza (KV vs. INGREZZA), used to treat tardive dyskinesia and chorea associated with Huntington's disease. The settlement, announced on November 9, 2023, allows Lupin to sell generic
United States. Securities and Exchange Commission
Centene Corporation, a healthcare company operating in the United States, has filed a Form 8-K report with the U.S. Securities and Exchange Commission disclosing the company's performance in the 2024 Medicare Advantage Star Ratings issued by the Centers for Medicare and Medicaid Services. According to the report,
United States. Securities and Exchange Commission
Elevance Health's affiliated health plans have seen a significant drop in their Medicare Advantage Star Ratings, with the percentage of members in 4-star or higher-rated plans expected to decline to approximately 34% as of 2024, compared to 64% in 2023. This decline is primarily driven by three large
